Investing

Replimune Group : REPL

REPL

Stock Data

$12.13

$0.73 (5.66%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Replimune Group Inc is a pioneering biotechnology firm based in Woburn, Massachusetts, dedicated to developing innovative cancer treatments. Founded in 2015, the company focuses on oncolytic immunotherapies, a cutting-edge approach that uses viruses to stimulate the immune system against cancer. Its flagship product, RP1, is a modified herpes virus in advanced clinical trials for various solid tumors, including a completed study for cutaneous squamous cell carcinoma. Replimune is also working on RP2 and RP3, early-stage therapies designed to enhance immune responses to cancer.

All Replimune Group Articles

1 Article

Lee Jackson | Aug 4, 2026 at 8:11 AM EDT

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, CoreWeave, eBay, Exxon Mobil, Intuit, Nebius Group, Palantir Technologies, SK hynix, and More

Wall Street wasted no time Monday, sending the Nasdaq surging past 25,900 while analysts took aim at some of the…